T Cell Subtypes From Naive T Cells Suppliers For Served Medical Health Care Clinical Services

LIXTE is a drug discovery company that has a developed unique, proprietary, first in-class protein phosphatase inhibitor, LB-100, our lead clinical compound. LB-100 has potential widespread use as an anti-cancer agent when used alone and in ...

We are global leader in the laboratory diagnostics market, specializing in the immunodiagnostics and molecular diagnostics segments. For over 50 years we have been dealing with diagnostics to help physicians and patients make better decisions in the ...

BlueSky Immunotherapies GmbH (Ltd.) is a clinical-stage biotech company. The company’s business is based on its own proprietary, novel technology platform for interferon-inducing viral vectors (delNS). Interferons have immunostimulatory and ...

CellFE is a venture-backed company with a mission to make advanced therapies accessible to all by transforming the way gene therapies are manufactured. The company uses a microfluidics-based cell engineering platform that can be adapted universally ...

We want to empower people to deal with their malignant cells through their own immune system just like we deal with viral infections. Today’s cancer immunotherapies are powerful but, to the detriment of their effect, not very tumor-selective. ...

Vaccitech is a clinical stage T cell immunotherapy and vaccine company developing products to treat and prevent infectious disease and cancer. The company’s proprietary heterologous prime-boost platform comprises Chimpanzee Adenovirus Oxford ...

Celluris is the first company in Latin America to develop personalized treatment for cancer patients through CAR-T immunotherapy. This technique is based on the modification of the patient’s own cells into recognizing the tumor as a target, fighting ...